Diabetes is characterized by hyperglycemia and insulin resistance, which significantly increase the risk of morbidity and mortality. Syzygium cumini seeds have been used traditionally in the management of diabetes, though the precise molecular mechanisms underlying their effects are not yet fully understood. The present study aimed to elucidate the molecular mechanisms through which S. cumini seed extract exerts its beneficial effects in diabetes, employing a network pharmacology approach. The constituents of S. cumini seeds were identified from online databases. Eligible constituents were then used to identify target genes through four databases. Genes associated with diabetes were retrieved from two databases. The overlapping genes were selected as the target genes for further analysis. A protein–protein interaction network was constructed using Cytoscape and the STRING database, which helped identify hub genes. This network was then used to perform gene ontology and pathway enrichment analyses. Among the 66 identified constituents, 29 were eligible for inclusion in the analysis. Database screening revealed 986 genes targeted by the selected active constituents, with 392 genes associated with diabetes. Of these, 112 genes overlapped. Following network development, the top 10 hub genes with the highest degree scores were selected for pathway enrichment analysis. The pathway enrichment analysis indicated that S. cumini may exert beneficial effects in diabetes by modulating several pathways related to RNA-mediated miRNA transcription, AGE-RAGE signaling, and HIF-1 signaling through multiple genes. The underlying mechanisms may involve enhanced cellular responses to oxidative stress, improved oxidative stress metabolism, and an elevated anti-inflammatory response. The current study provides promising evidence of the beneficial effects of S. cumini seed therapy in the management of diabetes. The findings of this study offer a potential direction for future molecular research to confirm the efficacy of S. cumini seeds in diabetic conditions through the pathways described.
Citation: Vishal Dubey, Jignesh Kansagra, Bhargav Kamani, Varun Sureja. Network pharmacology study to identify molecular pathways involved in the anti-diabetic activity of Syzygium cumini seed constituents[J]. AIMS Molecular Science, 2025, 12(3): 255-271. doi: 10.3934/molsci.2025016
Diabetes is characterized by hyperglycemia and insulin resistance, which significantly increase the risk of morbidity and mortality. Syzygium cumini seeds have been used traditionally in the management of diabetes, though the precise molecular mechanisms underlying their effects are not yet fully understood. The present study aimed to elucidate the molecular mechanisms through which S. cumini seed extract exerts its beneficial effects in diabetes, employing a network pharmacology approach. The constituents of S. cumini seeds were identified from online databases. Eligible constituents were then used to identify target genes through four databases. Genes associated with diabetes were retrieved from two databases. The overlapping genes were selected as the target genes for further analysis. A protein–protein interaction network was constructed using Cytoscape and the STRING database, which helped identify hub genes. This network was then used to perform gene ontology and pathway enrichment analyses. Among the 66 identified constituents, 29 were eligible for inclusion in the analysis. Database screening revealed 986 genes targeted by the selected active constituents, with 392 genes associated with diabetes. Of these, 112 genes overlapped. Following network development, the top 10 hub genes with the highest degree scores were selected for pathway enrichment analysis. The pathway enrichment analysis indicated that S. cumini may exert beneficial effects in diabetes by modulating several pathways related to RNA-mediated miRNA transcription, AGE-RAGE signaling, and HIF-1 signaling through multiple genes. The underlying mechanisms may involve enhanced cellular responses to oxidative stress, improved oxidative stress metabolism, and an elevated anti-inflammatory response. The current study provides promising evidence of the beneficial effects of S. cumini seed therapy in the management of diabetes. The findings of this study offer a potential direction for future molecular research to confirm the efficacy of S. cumini seeds in diabetic conditions through the pathways described.
| [1] |
Minolin MT, Gayathri S (2020) A study to assess the effectiveness of structured teaching programme on management and prevention of diabetic emergency among diabetic patients attending medicine OPD at SMCH, Thandalam. Int J Midwifery Nurs Pract 3: 25-30. Available from: https://www.nursingpractice.net/article/view/63/3-1-16 
|
| [2] |
Jeong D, Mok J, Jeon D, et al. (2023) Prevalence and associated factors of diabetes mellitus among patients with tuberculosis in South Korea from 2011 to 2018: A nationwide cohort study. BMJ Open 13: e069642. https://doi.org/10.1136/bmjopen-2022-069642
|
| [3] |
Dubey V, Kansagra J, Sureja V, et al. (2024) Efficacy evaluation of Berberis aristata and Silybum marianum fixed dose combination on glycaemic and insulin resistance parameters in adult population: A systematic review and meta-analysis of randomized controlled trials. Futur J Pharm Sci 10: 28. https://doi.org/10.1186/s43094-024-00603-7
|
| [4] |
Lin X, Xu Y, Pan X, et al. (2020) Global, regional, and national burden and trend of diabetes in 195 countries and territories: An analysis from 1990 to 2025. Sci Rep 10: 14790. https://doi.org/10.1038/s41598-020-71908-9
|
| [5] |
Saeedi P, Salpea P, Karuranga S, et al. (2020) Mortality attributable to diabetes in 20–79 years old adults, 2019 estimates: Results from the International Diabetes Federation Diabetes Atlas, 9th edition. Diabetes Res Clin Pract 162: 108086. https://doi.org/10.1016/j.diabres.2020.108086
|
| [6] |
Sun H, Saeedi P, Karuranga S, et al. (2022) IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res Clin Pract 183: 109119. https://doi.org/10.1016/j.diabres.2021.109119
|
| [7] |
Davies MJ, Aroda VR, Collins BS, et al. (2022) Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 45: 2753-2786. https://doi.org/10.2337/dci22-0034
|
| [8] |
Wang X, Kang J, Liu Q, et al. (2020) Fighting diabetes mellitus: Pharmacological and non-pharmacological approaches. Curr Pharm Des 26: 4992-5001. https://doi.org/10.2174/1381612826666200728144200
|
| [9] | Raveendran AV, Chacko EC, Pappachan JM, et al. (2018) Non-pharmacological treatment options in the management of diabetes mellitus. Eur Endocrinol 14: 31-39. https://doi.org/10.17925/EE.2018.14.2.31 |
| [10] | Nimesh S, Ashwlayan VD (2018) Nutraceuticals in the management of diabetes mellitus. Pharm Pharmacol Int J 6: 114-120. Available from: https://medcraveonline.com/PPIJ/PPIJ-06-00166.pdf |
| [11] |
Ayyanar M, Subash-Babu P (2012) Syzygium cumini (L.) Skeels: A review of its phytochemical constituents and traditional uses. Asian Pac J Trop Biomed 2: 240-246. https://doi.org/10.1016/S2221-1691(12)60050-1
|
| [12] |
Atale N, Mishra CB, Kohli S, et al. (2021) Anti-inflammatory effects of S. cumini seed extract on gelatinase-B (MMP-9) regulation against hyperglycemic cardiomyocyte stress. Oxid Med Cell Longev 2021: 8839479. https://doi.org/10.1155/2021/8839479
|
| [13] | Helmstädter A (2008) Syzygium cumini (L.) SKEELS (Myrtaceae) against diabetes-125 years of research. Pharmazie 63: 91-101. Available from: https://pubmed.ncbi.nlm.nih.gov/18380393/ |
| [14] |
Dongre P, Majumdar A (2024) Network pharmacology analysis of Chandraprabha Vati: A new hope for the treatment of Metabolic Syndrome. J Ayurveda Integr Med 15: 100902. https://doi.org/10.1016/j.jaim.2024.100902
|
| [15] |
Sharma B, Yadav DK (2022) Metabolomics and network pharmacology in the exploration of the multi-targeted therapeutic approach of traditional medicinal plants. Plants 11: 3243. https://doi.org/10.3390/plants11233243
|
| [16] |
Mohanraj K, Karthikeyan BS, Vivek-Ananth RP, et al. (2018) IMPPAT: A curated database of Indian medicinal plants, phytochemistry and therapeutics. Sci Rep 8: 4329. https://doi.org/10.1038/s41598-018-22631-z
|
| [17] |
Kim S, Chen J, Cheng T, et al. (2023) PubChem 2023 update. Nucleic Acids Res 51: D1373-D1380. https://doi.org/10.1093/nar/gkac956
|
| [18] |
Daina A, Michielin O, Zoete V (2017) SwissADME: A free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Sci Rep 7: 42717. https://doi.org/10.1038/srep42717
|
| [19] |
Daina A, Michielin O, Zoete V (2019) SwissTargetPrediction: Updated data and new features for efficient prediction of protein targets of small molecules. Nucleic Acids Res 47: W357-W364. https://doi.org/10.1093/nar/gkz382
|
| [20] |
Nickel J, Gohlke BO, Erehman J, et al. (2014) SuperPred: Update on drug classification and target prediction. Nucleic Acids Res 42: W26-W31. https://doi.org/10.1093/nar/gku477
|
| [21] |
Gu S, Lai LH (2020) Associating 197 Chinese herbal medicine with drug targets and diseases using the similarity ensemble approach. Acta Pharmacol Sin 41: 432-438. https://doi.org/10.1038/s41401-019-0306-9
|
| [22] |
Gilson MK, Liu T, Baitaluk M, et al. (2016) BindingDB in 2015: A public database for medicinal chemistry, computational chemistry and systems pharmacology. Nucleic Acids Res 44: D1045-D1053. https://doi.org/10.1093/nar/gkv1072
|
| [23] | Piñero J, Ramírez-Anguita JM, Saüch-Pitarch J, et al. (2020) The DisGeNET knowledge platform for disease genomics: 2019 update. Nucleic Acids Res 48: D845-D855. https://doi.org/10.1093/nar/gkz1021 |
| [24] |
Davis AP, Wiegers TC, Johnson RJ, et al. (2023) Comparative Toxicogenomics Database (CTD): Update 2023. Nucleic Acids Res 51: D1257-D1262. https://doi.org/10.1093/nar/gkac833
|
| [25] |
Szklarczyk D, Kirsch R, Koutrouli M, et al. (2023) The STRING database in 2023: Protein-protein association networks and functional enrichment analyses for any sequenced genome of interest. Nucleic Acids Res 51: D638-D646. https://doi.org/10.1093/nar/gkac1000
|
| [26] |
Doncheva NT, Morris JH, Gorodkin J, et al. (2019) Cytoscape StringApp: Network analysis and visualization of proteomics data. J Proteome Res 18: 623-632. https://doi.org/10.1021/acs.jproteome.8b00702
|
| [27] |
Majeed A, Mukhtar S (2023) Protein-protein interaction network exploration using Cytoscape. Protein-protein interactions 2690: 419-427. https://doi.org/10.1007/978-1-0716-3327-4_32
|
| [28] |
Chin CH, Chen SH, Wu HH, et al. (2014) cytoHubba: Identifying hub objects and sub-networks from complex interactome. BMC Syst Biol 8: S11. https://doi.org/10.1186/1752-0509-8-S4-S11
|
| [29] |
Kaur J, Farooqi H, Chandra K, et al. (2024) Predicting the bioactive compounds of Lentinula edodes and elucidating its interaction with genes associated to obesity through network pharmacology and in-vitro cell-based assay. Heliyon 10: e27363. https://doi.org/10.1016/j.heliyon.2024.e27363
|
| [30] |
Tang D, Chen M, Huang X, et al. (2023) SRplot: A free online platform for data visualization and graphing. PLoS One 18: e0294236. https://doi.org/10.1371/journal.pone.0294236
|
| [31] | The Gene Ontology Consortium.Gene ontology consortium: Going forward. Nucleic Acids Res (2015) 43: D1049-D1056. https://doi.org/10.1093/nar/gku1179 |
| [32] |
Kanehisa M, Furumichi M, Sato Y, et al. (2023) KEGG for taxonomy-based analysis of pathways and genomes. Nucleic Acids Res 51: D587-D592. https://doi.org/10.1093/nar/gkac963
|
| [33] |
Ayyanar M, Subash-Babu P, Ignacimuthu S (2013) Syzygium cumini (L.) Skeels., a novel therapeutic agent for diabetes: folk medicinal and pharmacological evidences. Complement Ther Med 21: 232-243. https://doi.org/10.1016/j.ctim.2013.03.004
|
| [34] |
Srivastava S, Chandra D (2013) Pharmacological potentials of Syzygium cumini: A review. J Sci Food Agric 93: 2084-2093. https://doi.org/10.1002/jsfa.6111
|
| [35] |
Teixeira CC, Fuchs FD, Weinert LS, et al. (2006) The efficacy of folk medicines in the management of type 2 diabetes mellitus: Results of a randomized controlled trial of Syzygium cumini (L.) Skeels. J Clin Pharm Ther 31: 1-5. https://doi.org/10.1111/j.1365-2710.2006.00700.x
|
| [36] |
Gurzov EN, Eizirik DL (2011) Bcl-2 proteins in diabetes: Mitochondrial pathways of β-cell death and dysfunction. Trends Cell Biol 21: 424-431. https://doi.org/10.1016/j.tcb.2011.03.001
|
| [37] |
Warren CFA, Wong-Brown MW, Bowden NA (2019) BCL-2 family isoforms in apoptosis and cancer. Cell Death Dis 10: 177. https://doi.org/10.1038/s41419-019-1407-6
|
| [38] |
Tinahones FJ, Aragüez LC, Murri M, et al. (2013) Caspase induction and BCL2 inhibition in human adipose tissue: A potential relationship with insulin signaling alteration. Diabetes Care 36: 513-521. https://doi.org/10.2337/dc12-0194
|
| [39] |
Bangar NS, Dixit A, Apte MM, et al. (2025) Syzygium cumini (L.) skeels mitigate diabetic nephropathy by regulating Nrf2 pathway and mitocyhondrial dysfunction: In vitro and in vivo studies. J Ethnopharmacol 336: 118684. https://doi.org/10.1016/j.jep.2024.118684
|
| [40] |
Khodavirdipour A, Zarean R, Safaralizadeh R (2021) Evaluation of the anti-cancer effect of Syzygium cumini ethanolic extract on HT-29 colorectal cell line. J Gastrointest Canc 52: 575-581. https://doi.org/10.1007/s12029-020-00439-3
|
| [41] |
Semenza GL (2012) Hypoxia-inducible factors in physiology and medicine. Cell 148: 399-408. https://doi.org/10.1016/j.cell.2012.01.021
|
| [42] |
Weidemann A, Johnson RS (2008) Biology of HIF-1α. Cell Death Differ 15: 621-627. https://doi.org/10.1038/cdd.2008.12
|
| [43] |
Gunton JE (2020) Hypoxia-inducible factors and diabetes. J Clin Invest 130: 5063-5073. https://doi.org/10.1172/JCI137556
|
| [44] |
Catrina SB, Zheng X (2021) Hypoxia and hypoxia-inducible factors in diabetes and its complications. Diabetologia 64: 709-716. https://doi.org/10.1007/s00125-021-05380-z
|
| [45] |
Liu T, Zhang L, Joo D, et al. (2017) NF-κB signaling in inflammation. Sig Transduct Target Ther 2: 17023. https://doi.org/10.1038/sigtrans.2017.23
|
| [46] |
Yu H, Lin L, Zhang Z, et al. (2020) Targeting NF-κB pathway for the therapy of diseases: Mechanism and clinical study. Sig Transduct Target Ther 5: 209. https://doi.org/10.1038/s41392-020-00312-6
|
| [47] |
Hashimoto R, Ohi K, Yasuda Y, et al. (2011) Variants of the RELA gene are associated with schizophrenia and their startle responses. Neuropsychopharmacology 36: 1921-1931. https://doi.org/10.1038/npp.2011.78
|
| [48] |
Patel S, Santani D (2009) Role of NF-κB in the pathogenesis of diabetes and its associated complications. Pharmacol Rep 61: 595-603. https://doi.org/10.1016/s1734-1140(09)70111-2
|
| [49] | Swami SB, Thakor NSJ, Patil MM, et al. (2012) Jamun (Syzygium cumini (L.)): A review of its food and medicinal uses. Food Nutr Sci 3: 1100-1117. https://doi.org/10.4236/fns.2012.38146 |
| [50] |
Apte MM, Khattar E, Tupe RS (2024) Mechanistic role of Syzygium cumini (L.) Skeels in glycation induced diabetic nephropathy via RAGE–NF–κB pathway and extracellular proteins modifications: A molecular approach. J Ethnopharmacol 322: 117573. https://doi.org/10.1016/j.jep.2023.117573
|
| [51] |
Dinarello CA, Donath MY, Mandrup-Poulsen T (2010) Role of IL-1beta in type 2 diabetes. Curr Opin Endocrinol 17: 314-321. https://doi.org/10.1097/MED.0b013e32833bf6dc
|
| [52] |
Dinarello CA (2011) Interleukin-1 in the pathogenesis and treatment of inflammatory diseases. Blood 117: 3720-3732. https://doi.org/10.1182/blood-2010-07-273417
|
| [53] |
Tanaka T, Narazaki M, Kishimoto T (2014) IL-6 in inflammation, immunity, and disease. Cold Spring Harb Perspect Biol 6: a016295. https://doi.org/10.1101/cshperspect.a016295
|
| [54] |
Rehman K, Akash MSH, Liaqat A, et al. (2017) Role of Interleukin-6 in development of insulin resistance and type 2 diabetes mellitus. Crit Rev Eukaryot Gene Expr 27: 229-236. https://doi.org/10.1615/CritRevEukaryotGeneExpr.2017019712
|
| [55] |
Pirola L, Ferraz JC (2017) Role of pro- and anti-inflammatory phenomena in the physiopathology of type 2 diabetes and obesity. World J Biol Chem 8: 120-128. https://doi.org/10.4331/wjbc.v8.i2.120
|
| [56] |
Khin PP, Lee JH, Jun HS (2023) Pancreatic beta-cell dysfunction in type 2 diabetes. Eur J Inflamm 21: 1721727X231154152. https://doi.org/10.1177/1721727X231154152
|
| [57] |
Alzamil H (2020) Elevated serum TNF-α is related to obesity in type 2 diabetes mellitus and is associated with glycemic control and insulin resistance. J Obes 2020: 5076858. https://doi.org/10.1155/2020/5076858
|
| [58] |
Cheng D, Fei Y, Saulnier PJ, et al. (2020) Circulating TNF receptors and risk of renal disease progression, cardiovascular disease events and mortality in patients with diabetes: a systematic review and meta-analysis. Endocrine 68: 32-43. https://doi.org/10.1007/s12020-019-02153-y
|
| [59] |
Aggarwal BB, Kunnumakkara AB, Harikumar KB, et al. (2009) Signal transducer and activator of transcription-3, inflammation, and cancer: How intimate is the relationship. Ann N Y Acad Sci 1171: 59-76. https://doi.org/10.1111/j.1749-6632.2009.04911.x
|
| [60] | Sarvas JL, Khaper N, Lees SJ (2013) The IL-6 paradox: Context dependent interplay of SOCS3 and AMPK. J Diabetes Metab S13: 003. https://doi.org/10.4172/2155-6156.S13-003 |
| [61] |
Weng Q, Zhao M, Zheng J, et al. (2020) STAT3 dictates β-cell apoptosis by modulating PTEN in streptozocin-induced hyperglycemia. Cell Death Differ 27: 130-145. https://doi.org/10.1038/s41418-019-0344-3
|
| [62] |
Singh P, Bast F, Bhushan S, et al. (2019) Molecular docking and in vitro study of Syzygium cumini-derived natural compounds on receptor tyrosine kinases pathway components. Int J Bioinform Res Appl 15: 144-158. https://doi.org/10.1504/IJBRA.2019.099576
|
| [63] |
Wang H, Guo M, Wei H, et al. (2023) Targeting p53 pathways: Mechanisms, structures, and advances in therapy. Signal Transduct Target Ther 8: 92. https://doi.org/10.1038/s41392-023-01347-1
|
| [64] |
Kung CP, Murphy ME (2016) The role of the p53 tumor suppressor in metabolism and diabetes. J Endocrinol 231: R61-R75. https://doi.org/10.1530/JOE-16-0324
|
| [65] | Younessi P, Yoonessi A (2011) Advanced glycation end-products and their receptor-mediated roles: Inflammation and oxidative stress. Iran J Med Sci 36: 154-166. |
| [66] |
Khalid M, Petroianu G, Adem A (2022) Advanced glycation end products and diabetes mellitus: Mechanisms and perspectives. Biomolecules 12: 542. https://doi.org/10.3390/biom12040542
|
| [67] |
Diener C, Keller A, Meese E (2022) Emerging concepts of miRNA therapeutics: From cells to clinic. Trends Genet 38: 613-626. https://doi.org/10.1016/j.tig.2022.02.006
|
| [68] |
de Sousa MC, Gjorgjieva M, Dolicka D, et al. (2019) Deciphering miRNAs' action through miRNA editing. Int J Mol Sci 20: 6249. https://doi.org/10.3390/ijms20246249
|
| [69] | Kim M, Zhang X (2019) The profiling and role of miRNAs in diabetes mellitus. J Diabetes Clin Res 1: 5-23. https://doi.org/10.33696/diabetes.1.003 |
| [70] |
Rezk NA, Sabbah NA, Saad MSS (2016) Role of microRNA 126 in screening, diagnosis, and prognosis of diabetic patients in Egypt. IUBMB Life 68: 452-458. https://doi.org/10.1002/iub.1502
|
| [71] |
Wang C, Wan S, Yang T, et al. (2016) Increased serum microRNAs are closely associated with the presence of microvascular complications in type 2 diabetes mellitus. Sci Rep 6: 20032. https://doi.org/10.1038/srep20032
|
 molsci-12-03-016-s001.pdf |
 |
Figures(5) / Tables(2)
Vishal Dubey, Jignesh Kansagra, Bhargav Kamani, Varun Sureja. Network pharmacology study to identify molecular pathways involved in the anti-diabetic activity of Syzygium cumini seed constituents[J]. AIMS Molecular Science, 2025, 12(3): 255-271. doi: 10.3934/molsci.2025016
DownLoad: